Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001

Safety aspects of AL001 development may qualify for a 505 NDA pathway for FDA approval




Alzamend recently completed a Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects...

Related Keywords

Florida ,United States ,Americans ,American ,Stephan Jackman ,Drug Administration ,Nasdaq ,Alzamend Neuro Inc ,American Psychiatric Association ,Exchange Commission ,Securities Exchange ,University Of South Florida Research Foundation Inc ,World Health Organization ,Alzamend Neuro ,Chief Executive Officer ,Statistical Manual ,Mental Disorders ,South Florida Research Foundation ,Securities Act ,Securities Exchange Act ,Markets ,